Cite
HARVARD Citation
Goldberg, S. et al. (n.d.). 3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC. European journal of cancer. pp. S627-. [Online].